GlassScriptPhysician profile
Mark Whitworth
NPI 1902369523
$6,852.65
in general payments reported to CMS, 2019-2025
39 companies · $2,341 in 2025
The $2,341 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $486 · 2023: $1,520 · 2024: $2,506 · 2025: $2,341.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,353 · Entertainment: $13.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,353.49 |
| Entertainment | $13.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $973.04 | 2022-2025 | Ubrelvy, Vraylar, Qulipta |
| Astrazeneca Pharmaceuticals LP | $602.95 | 2023-2025 | Breztri, Airsupra, Farxiga |
| Pfizer INC. | $562.07 | 2022-2025 | |
| Novo Nordisk INC | $487.27 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $487.08 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Otsuka America Pharmaceutical, INC. | $479.86 | 2023-2025 | Rexulti, Nuedexta |
| Bayer Healthcare Pharmaceuticals INC. | $471.21 | 2022-2025 | |
| Lilly USA, LLC | $409.80 | 2023-2025 | Mounjaro, Zepbound, Trulicity |
| Exact Sciences Corporation | $261.24 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Amgen INC. | $227.44 | 2023-2025 | Otezla, Repatha, Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $220.31 | 2023-2025 | Xifaxan, Relistor |
| Dexcom, INC. | $173.19 | 2023-2025 | Dexcom G6 Transmitter |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $164.48 | 2024-2025 | Caplyta |
| Ardelyx, INC. | $144.48 | 2024-2025 | Ibsrela |
| Shield Therapeutics INC | $118.98 | 2023-2025 | Accrufer |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $116.17 | 2024-2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $102.07 | 2022-2024 | Trintellix |
| Teva Pharmaceuticals USA, INC. | $100.47 | 2023-2025 | Austedo, Austedo Xr |
| Xeris Pharmaceuticals, INC. | $67.97 | 2022-2025 | Recorlev, Gvoke Hypopen |
| Antares Pharma, INC. | $64.83 | 2024-2025 | Xyosted, Tlando |
| Lundbeck LLC | $62.90 | 2024-2025 | Rexulti |
| Phathom Pharmaceuticals, INC. | $56.73 | 2024 | Voquezna |
| Idorsia Pharmaceuticals US INC | $49.98 | 2023-2024 | Quviviq |
| Neurelis, INC. | $42.91 | 2024 | Valtoco |
| Paratek Pharmaceuticals, INC. | $42.14 | 2025 | Nuzyra, Xhance |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $38.60 | 2025 | Rexulti |
| Corcept Therapeutics | $38.55 | 2023 | Korlym |
| Sanofi-Aventis U.S. LLC | $37.15 | 2023 | |
| Novartis Pharmaceuticals Corporation | $31.97 | 2024 | |
| Allergan, INC. | $31.03 | 2022 | |
| Sk Life Science, INC. | $30.86 | 2023 | |
| Tris Pharma INC | $22.95 | 2025 | Dyanavel Xr |
| Halozyme INC | $21.07 | 2023 | |
| Supernus Pharmaceuticals, INC. | $21.05 | 2022 | Xyosted, Tlando |
| Boston Scientific Corporation | $20.96 | 2024 | |
| Nestle Healthcare Nutrition INC. | $19.29 | 2023 | |
| Horizon Therapeutics Plc | $18.59 | 2023 | Krystexxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.36 | 2025 | Jardiance |
| Optos, INC. | $13.65 | 2025 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Whitworth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.